- Home
- IPSC vs ALGS Comparison
IPSC vs ALGS Comparison
Compare IPSC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPSC | ALGS |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8M | 57.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IPSC | ALGS |
|---|---|---|
| Price | $0.58 | $12.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 934.8K | 81.5K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | $2,646,000.00 |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $3.76 |
| 52 Week High | $1.38 | $46.80 |
Technical Indicators
Market Signals| Indicator | IPSC | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 67.32 |
| Support Level | $0.50 | $9.10 |
| Resistance Level | $0.62 | $10.45 |
| Average True Range (ATR) | 0.04 | 0.84 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 64.59 | 66.24 |
Price Performance
Historical ComparisonAbout IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.